T2 Biosystems Tackles Sepsis Testing

The video discusses the challenges faced by the diagnostic industry, particularly related to reimbursement issues, and how T2 is not affected due to its unique approach to sepsis testing. T2 differentiates itself from Theranos by placing instruments in hospitals for rapid testing, which saves costs and improves accuracy. T2 has developed a new diagnostic detection method, backed by 50 patents and FDA approval, and is making a significant impact globally by detecting infections missed by traditional blood culture methods.

What is the primary reason T2 is not affected by reimbursement issues in the diagnostic industry?

• They have a unique testing method.

• They have a large market share.

• They save hospitals money with their products.

• They operate in a different industry.

How does T2 ensure rapid turnaround time for their tests?

• By using faster transportation methods.

• By using a central lab for testing.

• By placing instruments in hospitals.

• By outsourcing tests to third parties.

What is a key difference between T2 and Theranos according to the transcript?

• T2 focuses on a different type of disease.

• T2 has a larger team of scientists.

• T2 places instruments in hospitals for testing.

• T2 uses a different type of blood sample.

What supports T2's new diagnostic detection method?

• 50 issued patents and peer-reviewed data.

• Government funding.

• A large marketing campaign.

• A partnership with Theranos.

What percentage of infections does T2's technology detect compared to blood culture?

• 100%

• 96%

• 75%

• 50%